<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838159</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 18/02_NADIM II</org_study_id>
    <nct_id>NCT03838159</nct_id>
  </id_info>
  <brief_title>NADIM II: Neo-Adjuvant Immunotherapy</brief_title>
  <acronym>NADIMII</acronym>
  <official_title>A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial.

      90 patients will be enrolled in this trial to examine the pathological Complete Response
      defined as the absence of residual tumor in lung and lymph nodes comparing patients treated
      with chemo-immunotherapy versus chemotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. Patients
      randomised to the experimental arm will receive Nivolumab 360mg + Paclitaxel 200mg/m2 +
      Carboplatin AUC5 for 3 cycles every 21 days (+/- 3 days) as neoadjuvant treatment followed by
      surgery and 1 year of adjuvant treatment with Nivolumab 240 mg Q2W (+/- 3 days) and 8 months
      with nivolumab 480 mg Q4W. Patients randomized to the control arm will receive Paclitaxel
      200mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/- 3 days) followed by surgery.

      The primary objective is pathological Complete Response (pCR) defined as the absence of
      residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy
      versus chemotherapy alone. Patient accrual is expected to be completed within 3 years
      excluding a run-in-period of 3 months. Treatment and follow-up are expected to extend the
      study duration to a total of 6.5 years. Patients will be followed 3 years after adjuvant
      treatment or surgery. The study will end once survival follow-up has concluded.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the pathological complete response (pCR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 45 months.</time_frame>
    <description>The pathological complete response is defined as the absence of residual tumor in lung and lymph nodes in patients treated with chemo-immunotherapy versus patients treated with chemotherapy alone.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant treatment (paclitaxel+carboplatin+nivolumab) will start within 1-3 days from enrollment/randomisation. 3 cycles will be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)
Adjuvant treatment (Nivolumab): Patients that are R0 confirmed by surgical pathology evaluation will receive the first adjuvant administration within the 3rd to 8th week (+ 7 days) from surgery and for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Neo-Adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant treatment (paclitaxel+carboplatin) will start within 1-3 days from enrollment/ randomisation. 3 cycleswill be administered at 21-day (+/- 3 days) intervals (QW3) prior to surgery. Before surgery a tumor assessment will be done. Patients must leave the study if there is evidence of progression. Patients with stable disease or partial response may be considered for surgery.
Surgery: Surgery must be done within the 3rd-4th week (+7 days) from day 21 cycle 3 of neoadjuvant treatment (day 42-49 after day 1 of cycle 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.
In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected.</description>
    <arm_group_label>Control: Neo-Adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin must be administered at the end of the Paclitaxel infusion</description>
    <arm_group_label>Control: Neo-Adjuvant chemotherapy</arm_group_label>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.
The administration of nivolumab infusion must be completed within 24 hours of preparation.</description>
    <arm_group_label>Experimental: Neo-Adjuvant Immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously untreated patients with histologically- or cytologically- documented NSCLC
             who present stage IIIA disease (according to 8th version of the International
             Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and
             also, potentially resectable locally advanced NSCLC patients' stage IIIB with T3N2
             disease according to 8th edition can be included.

               -  PET/CT including IV contrast (CT of diagnostic quality) will be performed at
                  baseline (28 days +10 before randomization)

          2. Tumor should be considered resectable before study entry by a multidisciplinary team

          3. ECOG (Performance status) 0-1

          4. Screening laboratory values must meet the following criteria and should be obtained
             within 14 days prior to randomization.

             i. Neutrophils ≥ 1500×109/L ii. Platelets ≥ 100 x×109/L iii. Hemoglobin &gt; 9.0 g/dL iv.
             Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min v. AST/ALT ≤ 3
             x ULN vi. Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can
             have total bilirubin &lt; 3.0 mg/dL) vii. The patients need to have a forced expiratory
             volume (FEV1) ≥ 1.2 liters or &gt;40% predicted value viii. INR/APTT within normal limits

          5. All patients are notified of the investigational nature of this study and signed a
             written informed consent in accordance with institutional and national guidelines,
             including the Declaration of Helsinki prior to any trial-related intervention

          6. Patients aged &gt; 18 years

          7. Women of childbearing potential, including women who had their last menstrual period
             in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
             before randomization.

          8. All sexually active men and women of childbearing potential must use an effective
             contraceptive method (two barrier methods or a barrier method plus a hormonal method)
             during the study treatment and for a period of at least 12 months following the last
             administration of trial drugs

          9. Patient capable of proper therapeutic compliance and accessible for correct follow-up

         10. Measurable or evaluable disease (according to RECIST 1.1 criteria)

        Exclusion Criteria:

          1. All patients carrying activating mutations in the TK domain of EGFR or any variety of
             alterations in the ALK gene.

          2. Patients with active, known or suspected autoimmune disease. Subjects with vitiligo,
             type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only
             requiring hormone replacement or unexpected conditions of recurrence in the absence of
             an external trigger are allowed to be included.

          3. Patients with a condition requiring systemic treatment with either corticosteroids
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of randomization. Inhaled or topical steroids, and adrenal replacement steroid
             doses &gt; 10 mg daily prednisone equivalent, are permitted in the absence of active
             autoimmune disease.

          4. Patients with a history of interstitial lung disease cannot be included if they have
             symptomatic ILD (Grade 3-4) and/or poor lung function. In case of doubt please contact
             trial team.

          5. Patients with other active malignancy requiring concurrent intervention and/or
             concurrent treatment with other investigational drugs or anti-cancer therapy

          6. Patients with previous malignancies (except non-melanoma skin cancers, and the
             following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia,
             melanoma, or breast) are excluded unless a complete remission was achieved at least 2
             years prior to study entry AND no additional therapy is required during the study
             period.

          7. Any medical, mental or psychological condition which in the opinion of the
             investigator would not permit the patient to complete the study or understand the
             patient information

          8. Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell
             costimulation or immune checkpoint pathways

          9. Patients with positive test for hepatitis B virus surface antigen (HBV sAg) or
             hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic
             infection

         10. Patients with known history of testing positive for human immunodeficiency virus (HIV)
             or known acquired immunodeficiency syndrome (AIDS)

         11. Patients with history of allergy to study drug components excipients

         12. Women who are pregnant or in the period of breastfeeding

         13. Sexually active men and women of childbearing potential who are not willing to use an
             effective contraceptive method during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariano Provencio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Puerta del Hierro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Pereira</last_name>
    <phone>+34934302006</phone>
    <email>epereira@gecp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Morán, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enric Carcereny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Nadal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ernest Nadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delvys Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delvys Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario García, MD-phD</last_name>
    </contact>
    <investigator>
      <last_name>Rosario García</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Calvo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Virginia Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Casal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquín Casal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo López, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillermo López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massutí, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bartomeu Massutí, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Viteri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Santiago Viteri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d' Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alex Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemí Reguart, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noemí Reguart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Majem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Majem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isidoro Barneto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isidoro Barneto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquim Bosch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquim Bosch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis González, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Luis González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dómine, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Dómine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Ponce, MD</last_name>
    </contact>
    <investigator>
      <last_name>Santiago Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de Castro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier de Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Cobo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Cobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira del Barco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elvira del Barco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Reyes Bernabé</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Insa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Insa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Camps, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Camps, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael López, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Isla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dolores Isla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

